HEFFICON

HIV effectiveness Italian conference

Andrea Antinori, Massimo Andreoni, Carlo Federico Perno, Adriano Lazzarin, Adriana Ammassari, Paolo Bonfanti, Stefano Bonora, Marco Borderi, Maria Rosaria Capobianchi, Antonella Castagna, Massimo Clementi, Paola Cinque, Antonella D'Arminio Monforte, Giovanni Di Perri, Massimo Galli, Andrea Gori, Paolo Maggi, Claudio Mastroianni, Cristina Mussini, Emanuale Nicastri & 4 others Massimo Puoti, Stefano Rusconi, Maria Santoro, Giuseppe Tambussi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Since the first acquired immunodeficiency syndrome cases were reported in 1981, more than 1.5 million people have been diagnosed with Human Immunodeficiency Virus-1 in Europe, including more than 136,000 new HIV cases in 2013. Recent epidemiological data estimate an incidence of 5-10 newly diagnosed HIV infections per 100,000 population per year in Europe and an average prevalence of infection of 5.7 cases per 100,000 population. In the absence of an effective curative strategy for HIV, optimization of prevention policies and clinical management of HIV positive patients is fundamental to reduce the impact of the HIV pandemic on public health. Clinical trials represent an essential tool for translating research findings into routine clinical practice. Careful evaluation and planning of clinical trials are therefore mandatory in order to provide relevant information to clinicians. The HEFFICON Project was conceived to investigate and pinpoint methodological issues and critical points that need to be addressed in future clinical studies to increase the translation of experimental results to the real life environment.

Original languageEnglish
Pages (from-to)149-184
Number of pages36
JournalNew Microbiologica
Volume38
Issue number2
Publication statusPublished - Apr 1 2015

Fingerprint

HIV
Clinical Trials
Pandemics
Population
HIV Infections
HIV-1
Acquired Immunodeficiency Syndrome
Public Health
Incidence
Infection
Research
Clinical Studies

Keywords

  • AIDS
  • HAART
  • HIV
  • Integrase inhibitors

ASJC Scopus subject areas

  • Microbiology (medical)
  • Medicine(all)

Cite this

HEFFICON : HIV effectiveness Italian conference. / Antinori, Andrea; Andreoni, Massimo; Perno, Carlo Federico; Lazzarin, Adriano; Ammassari, Adriana; Bonfanti, Paolo; Bonora, Stefano; Borderi, Marco; Capobianchi, Maria Rosaria; Castagna, Antonella; Clementi, Massimo; Cinque, Paola; D'Arminio Monforte, Antonella; Di Perri, Giovanni; Galli, Massimo; Gori, Andrea; Maggi, Paolo; Mastroianni, Claudio; Mussini, Cristina; Nicastri, Emanuale; Puoti, Massimo; Rusconi, Stefano; Santoro, Maria; Tambussi, Giuseppe.

In: New Microbiologica, Vol. 38, No. 2, 01.04.2015, p. 149-184.

Research output: Contribution to journalArticle

Antinori, A, Andreoni, M, Perno, CF, Lazzarin, A, Ammassari, A, Bonfanti, P, Bonora, S, Borderi, M, Capobianchi, MR, Castagna, A, Clementi, M, Cinque, P, D'Arminio Monforte, A, Di Perri, G, Galli, M, Gori, A, Maggi, P, Mastroianni, C, Mussini, C, Nicastri, E, Puoti, M, Rusconi, S, Santoro, M & Tambussi, G 2015, 'HEFFICON: HIV effectiveness Italian conference', New Microbiologica, vol. 38, no. 2, pp. 149-184.
Antinori A, Andreoni M, Perno CF, Lazzarin A, Ammassari A, Bonfanti P et al. HEFFICON: HIV effectiveness Italian conference. New Microbiologica. 2015 Apr 1;38(2):149-184.
Antinori, Andrea ; Andreoni, Massimo ; Perno, Carlo Federico ; Lazzarin, Adriano ; Ammassari, Adriana ; Bonfanti, Paolo ; Bonora, Stefano ; Borderi, Marco ; Capobianchi, Maria Rosaria ; Castagna, Antonella ; Clementi, Massimo ; Cinque, Paola ; D'Arminio Monforte, Antonella ; Di Perri, Giovanni ; Galli, Massimo ; Gori, Andrea ; Maggi, Paolo ; Mastroianni, Claudio ; Mussini, Cristina ; Nicastri, Emanuale ; Puoti, Massimo ; Rusconi, Stefano ; Santoro, Maria ; Tambussi, Giuseppe. / HEFFICON : HIV effectiveness Italian conference. In: New Microbiologica. 2015 ; Vol. 38, No. 2. pp. 149-184.
@article{8e5fc628e291420e87bb5eff7034b6d3,
title = "HEFFICON: HIV effectiveness Italian conference",
abstract = "Since the first acquired immunodeficiency syndrome cases were reported in 1981, more than 1.5 million people have been diagnosed with Human Immunodeficiency Virus-1 in Europe, including more than 136,000 new HIV cases in 2013. Recent epidemiological data estimate an incidence of 5-10 newly diagnosed HIV infections per 100,000 population per year in Europe and an average prevalence of infection of 5.7 cases per 100,000 population. In the absence of an effective curative strategy for HIV, optimization of prevention policies and clinical management of HIV positive patients is fundamental to reduce the impact of the HIV pandemic on public health. Clinical trials represent an essential tool for translating research findings into routine clinical practice. Careful evaluation and planning of clinical trials are therefore mandatory in order to provide relevant information to clinicians. The HEFFICON Project was conceived to investigate and pinpoint methodological issues and critical points that need to be addressed in future clinical studies to increase the translation of experimental results to the real life environment.",
keywords = "AIDS, HAART, HIV, Integrase inhibitors",
author = "Andrea Antinori and Massimo Andreoni and Perno, {Carlo Federico} and Adriano Lazzarin and Adriana Ammassari and Paolo Bonfanti and Stefano Bonora and Marco Borderi and Capobianchi, {Maria Rosaria} and Antonella Castagna and Massimo Clementi and Paola Cinque and {D'Arminio Monforte}, Antonella and {Di Perri}, Giovanni and Massimo Galli and Andrea Gori and Paolo Maggi and Claudio Mastroianni and Cristina Mussini and Emanuale Nicastri and Massimo Puoti and Stefano Rusconi and Maria Santoro and Giuseppe Tambussi",
year = "2015",
month = "4",
day = "1",
language = "English",
volume = "38",
pages = "149--184",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "2",

}

TY - JOUR

T1 - HEFFICON

T2 - HIV effectiveness Italian conference

AU - Antinori, Andrea

AU - Andreoni, Massimo

AU - Perno, Carlo Federico

AU - Lazzarin, Adriano

AU - Ammassari, Adriana

AU - Bonfanti, Paolo

AU - Bonora, Stefano

AU - Borderi, Marco

AU - Capobianchi, Maria Rosaria

AU - Castagna, Antonella

AU - Clementi, Massimo

AU - Cinque, Paola

AU - D'Arminio Monforte, Antonella

AU - Di Perri, Giovanni

AU - Galli, Massimo

AU - Gori, Andrea

AU - Maggi, Paolo

AU - Mastroianni, Claudio

AU - Mussini, Cristina

AU - Nicastri, Emanuale

AU - Puoti, Massimo

AU - Rusconi, Stefano

AU - Santoro, Maria

AU - Tambussi, Giuseppe

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Since the first acquired immunodeficiency syndrome cases were reported in 1981, more than 1.5 million people have been diagnosed with Human Immunodeficiency Virus-1 in Europe, including more than 136,000 new HIV cases in 2013. Recent epidemiological data estimate an incidence of 5-10 newly diagnosed HIV infections per 100,000 population per year in Europe and an average prevalence of infection of 5.7 cases per 100,000 population. In the absence of an effective curative strategy for HIV, optimization of prevention policies and clinical management of HIV positive patients is fundamental to reduce the impact of the HIV pandemic on public health. Clinical trials represent an essential tool for translating research findings into routine clinical practice. Careful evaluation and planning of clinical trials are therefore mandatory in order to provide relevant information to clinicians. The HEFFICON Project was conceived to investigate and pinpoint methodological issues and critical points that need to be addressed in future clinical studies to increase the translation of experimental results to the real life environment.

AB - Since the first acquired immunodeficiency syndrome cases were reported in 1981, more than 1.5 million people have been diagnosed with Human Immunodeficiency Virus-1 in Europe, including more than 136,000 new HIV cases in 2013. Recent epidemiological data estimate an incidence of 5-10 newly diagnosed HIV infections per 100,000 population per year in Europe and an average prevalence of infection of 5.7 cases per 100,000 population. In the absence of an effective curative strategy for HIV, optimization of prevention policies and clinical management of HIV positive patients is fundamental to reduce the impact of the HIV pandemic on public health. Clinical trials represent an essential tool for translating research findings into routine clinical practice. Careful evaluation and planning of clinical trials are therefore mandatory in order to provide relevant information to clinicians. The HEFFICON Project was conceived to investigate and pinpoint methodological issues and critical points that need to be addressed in future clinical studies to increase the translation of experimental results to the real life environment.

KW - AIDS

KW - HAART

KW - HIV

KW - Integrase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84930983963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930983963&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 149

EP - 184

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 2

ER -